Healthy Living/WellnessBioMarin Drug Fails To Show Benefit In Inattention, Mood Complications Among Patients With PAH Deficiency A new drug developed by BioMarin Pharmaceuticals showed promise in lowering phenylalanine in the blood of patients with phenylalanine hydroxylase deficiency. However, it failed to show benefit in mood complications and inattention.by Angela Laguipo
Healthy Living/WellnessAustralia Funding $3.3 Million Study On 'Wind Turbine Sickness'by Jereal Cawis
Healthy Living/WellnessDumb Blonde Stereotype Is Wrong: Study Finds No Link Between Hair Color And Intelligenceby Katherine Derla
Healthy Living/WellnessCinqair Receives FDA Approval As Treatment For Severe Asthmaby Rina Marie Doctor
Healthy Living/WellnessBenefits Of Drinking Alcohol Regularly Overrated: Studyby Catherine Cabral-Isabedra
Healthy Living/WellnessMore Ancient Viruses Lay Dormant In Human DNA Than Previously Thoughtby Angela Laguipo